Teicoplanin administration for treating Gram-positive infections
Use of Teicoplanin on a Three-weekly Administration in the Complex Outpatient Macroactivity Regimen of Infectious Diseases Unit in the Alessandro Manzoni Hospital (Lecco, Italy)
This study tests if giving teicoplanin three times a week can help patients with Gram-positive infections, like MRSA, get better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Azienda Ospedaliera di Lecco Academic / other |
| Locations | 1 site (Lecco) |
| Trial ID | NCT06426212 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of administering teicoplanin three times a week for patients with documented Gram-positive infections. Teicoplanin is an antibiotic that targets various Gram-positive bacteria, including MRSA and Enterococcus spp. The study focuses on patients who have received at least four doses of teicoplanin, either alone or with other antibiotics, to assess its impact on infection outcomes. The research aims to gather data on the administration schedule and its efficacy in treating specific infections.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with documented Gram-positive infections that are sensitive to teicoplanin and who have received at least four doses of the medication.
Not a fit: Patients who are hospitalized or have received fewer than four doses of teicoplanin will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could optimize teicoplanin treatment regimens, leading to improved patient outcomes in managing Gram-positive infections.
How similar studies have performed: While teicoplanin has been used for many years, this specific administration schedule is being evaluated for the first time in this context, making it a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>18 years; * Patients with documented Gram-positive infection sensitive to teicoplanin; * Patients who have received at least 4 doses of teicoplanin on a three-weekly schedule, as monotherapy or associated with other antibiotics Exclusion Criteria: * Hospitalized patients * Patients who have received less than 4 doses of teicoplanin for any cause.
Where this trial is running
Lecco
- Stefania Piconi — Lecco, Italy (Recruiting)
Study contacts
- Study coordinator: Stefania Piconi, MD
- Email: s.piconi@asst-lecco.it
- Phone: +390341489890
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.